ERBB2 and neoplasm: Sharifzadeh et al. found that it was possible to develop oligoclonal nanobodies that target TAG-72 but that do no cross-react with HER2.30 Milenic et al. found that the dual targeting of 2 distinct molecules in tumors containing TAG-72 and HER2 with alpha particle radiation could result in an enhanced and additive therapeutic benefit in an animal tumor xenograft model [32].